OPTIMI IN THE NEWS: Drug companies see mushrooming growth in psychedelic therapy – Optimi Health OPTI (CNSX)

OPTIMI IN THE NEWS: Drug companies see mushrooming growth in psychedelic therapy

July 4, 2023
Optimi Health OPTI (CNSX)

Click on the link for full story.

TGA OKs mushrooming growth in psychedelic therapies (thenewdaily.com.au)

ABOUT OPTIMI

(CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

FORWARD‐LOOKING STATEMENTS

Optimi Health Corp.

21 Water St #600, Vancouver, BC V6B 1A1

Contact Information

E: investors@optimihealth.ca

T: +778-761-4551

Regulator Filings

Sedar Documents

Reporting – Modern Slavery Report 2024

Legal Counsel: Norton Rose Fulbright

Auditor: Smythe CPA

Transfer Agent: Endeavor Trust

Corporate Visibility & Investor Relations: Kydder Group

Trading Symbol: CSE: OPTI | OTC:OPTHF |

FRA: 8BN

CUSIP Number: 68405H100

ISIN Number: CA68405H1001

WKN: A2QQEL

Issued & Outstanding: (30/06/2022) 80,451,883

Incorporated: BC / May 27, 2020

Year End: September 30th

Product Disclaimer: Optimi Health products are still being investigated through a clinically validated development program for the purpose of applying for market authorization.

The safety and efficacy of our products has not been formally established.

© Copyright 2024 Optimi Health All rights reserved.